Member Info for Ghia

Jallis, Org - if the vaccine really was 95% effective there would be no need for such a slow exit from lockdown.

The vaccine claims are at odds with the governments actions.

Whitty openly acknowledge Covid is likely to be an issue every winter.

This plays into SNG’s hands another seasonal viral illness that mutates and will be difficult to vaccinate against. Lethal for the vulnerable and elderly.

"Vaccine reduces hospitalisations by 84% and 95%" When the entire country has been in lockdown for 2 months.

The slow and cautious exit to lockdown is because they know if we open right back up again cases will spike again.

For Synairgen the ultimate goal is to collect enough gold standard data to recieve approval. Covid has accelerated their program, probably cutting 1-2years out of the process.

If we recieve approval the job is done, this would have been a profitable drug without Covid it's worth will be even more understood now we have had a viral pandemic on this scale.

Could be a tumultuous few weeks ahead, an opportunity for those inclined to add more or those late to the party join.

If you are a long term holder here for goodness sake please don't loose your marbles so close to the finish line.

Immunity to Flu has been seriously hampered by the lack of mixing due to lockdowns. The next Flu season will be far bigger than usual SNG will become a household name.

Search function for chats or sticky posts.

Anyway better life has been discussed here at length.

Many papers suggest beta better than alpha for corona viruses.

Better life CEO publicly tried to trash talk SNG that’s not something a company that is confident in their product would do.

If you look at the way Holgate & co handle themselves it is an outfit with supreme confidence in their work.

When they do criticise others it is done in an above board and respectful manner.

ThinShins - I think you need to look a bit wider than just the UK. Vaccine penetration has barely scratched the surface of the global vulnerable population.

Don’t hate on me as this is only an opinion but I wouldn’t put sub £1 out the question here in the absence of news.

If it drops there again buy like crazy.

Amanensia - and there lies the problem the more successful BTC becomes the more of a global energy crisis it causes.

Sure you can use green sources of energy but until the world is using 100% green energy this seems an unnecessary waste of energy when there are better blockchain technology out there.

Blockchain has the potential to change many industries, BTC and mining companies do nothing to promote the best image for crypto.

Suggest people switch off and come back 3rd week of March.

Namron999 - I'm pretty sure the energy requirement to mine bitcoin to it's entirety will be at odds with the global desire to reduce emissions.

I expect Bitcoin will be shutdown before it is fully mined. Crypto will live on with the better blockchains but bitcoin has a shelf life. IMO of course.

Genuine question, it's looking like crypto is moving away from proof of work towards proof of stake.

My limited understanding of ARB is that it is a crypto miner, do they have a business model for when mining is no longer profitable and the popular coins are all proof of stake based?

The key to crypto will be the first blockchain that infiltrates the personal banking space this will take time but it will happen. But it won't be a proof of work coin.

The trick is to spot value where the market currently does not for whatever reason.

GDR, ODX, AVCT would all have been great buys a few weeks/months ago the market did not see the value it now does.

Conversely in hindsight NCYT was not the Best Buy a few weeks back.

It does however seem to be pretty good value right now.

I’d rather buy a stock that’s on a poor run due to lack of news (but strong underlying fundamentals) rather than a stock that has just put 50% on it’s MCap but has yet to deliver the revenue some future revenue is being built into those other companies.

A long time coming but GDR are finally competing and they’ve chosen the right market to do so.

The American market is huge and we have a first class partner so it’s a forgone conclusion that there will be some sales.

Mig - Put it this way I wouldn't want to risk being out of this after 14days from now. I think you've got a 2 week buying window before the earliest chance of any indication that a benefit is being seen.

28days is the formal end point for each patient, expect it to recruit pretty quickly. Data reviewed as they go and desire to roll out quickly.

Happy - Stick to your oil portfolio that seems to be doing very well for you...

I think everyone is well aware of the risks here we have two brokers that are putting a 70% chance of the drug getting to market, that’s very good odds for biotech.

Hopefully it doesn’t pop before the new tax year I’d love to have a second wedge in my ISA.

Capital - That's my experience too they love paperwork and then it's a struggle getting them to pay up on time. Lovely people though.

helped by a super bowl surge in infections...

Great news that it started recruiting 10th feb. A couple of weeks head start on the other treatments would be nice.

March really could be an exciting month.

Did anyone read the article? I sincerely hope the government do not fund a P1 trial for foramulab since we should be focusing on securing funding for a P2b.

The P3 hospital trial has started in the UK and will rollout globally.

Activ2 is a completely separate trial funded by the US government focusing on outpatient treatment. P2 has or is about to start, it will fill fast and data is reviewed as they go if P2 data is good it moves straight into P3 and EUA can be applied for whilst P3 is carrying on.